Novavax COVID-19 vaccine
vaccine against COVID-19
The Novavax COVID-19 vaccine, sold under the brand names Nuvaxovid and Covovax, among others, is a subunit COVID-19 vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations.
Updated versions of the vaccine have been developed to provide coverage against the Omicron variant, with different formulas for 2023–2024 (containing a recombinant spike protein from lineage XBB.1.5) and 2024–2025 (containing recombinant spike protein from lineage JN.1).
Medical uses
The Novavax COVID‑19 vaccine is indicated for active immunization to prevent COVID‑19 caused by SARS-CoV-2.
In the US, Nuvaxovid is indicated for active immunization to prevent COVID‑19 caused by SARS-CoV-2 in adults aged 65 years of age and older. Nuvaxovid is also indicated for individuals aged 12 through 64 years of age who have at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.
Efficacy
In December 2021, Novavax reported that its phase III trial showed the vaccine achieved its primary endpoint of preventing infection at least seven days after the second dose. Overall efficacy against different SARS-CoV-2s was 90.4% and efficacy against moderate-to-severe disease was 100%.
A vaccine is generally considered effective if the estimate is ≥50% with a >30% lower limit of the 95% confidence interval. Efficacy is closely related to effectiveness, which is generally expected to slowly decrease over time.
Side effects
The most common side effects include fever, headache, nausea, muscle and joint pain, tenderness and pain at the injection site, tiredness, and feeling unwell.
The public source identifies “Novavax COVID-19 vaccine” as vaccine against COVID-19. This brief keeps that definition visible, then builds a research path around Novavax, COVID-19 and vaccine.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Novavax COVID-19 vaccine”, the useful work is to connect “vaccine against COVID-19” to the records capable of establishing context and consequence.
Vocabulary and entity names are the principal evidence signals here, because they determine the precision of every later search. The source revision retrieved here is dated Jul 25, 2026. The linked authority identifier is Q97154235. None of the 1 selected statements returned an explicit reference. The first chronological checks are 2023, 2024, 2025 and 2021.
The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Novavax COVID-19 vaccine”, its source revision and the description used here.
- Expand the search: follow Novavax COVID-19 vaccine primary sources, Novavax COVID-19 vaccine archive and Novavax research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Novavax COVID-19 vaccine”?
- What terminology or title could unlock a more precise catalogue search?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “Novavax COVID-19 vaccine” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.